Icon
+91 94997 68112
Login Register

YEZTUGO - (463.5MG/1.5ML)

LENACAPAVIR None
463.5MG/1.5ML
Less Than $1000 mn
None None
None None
None None
YEZTUGO is indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating YEZTUGO
Yes
YEZTUGO Patent 1 Patent 2 Patent 3 Patent 4
*** *********

YEZTUGO - (463.5MG/1.5ML)

LENACAPAVIR None
463.5MG/1.5ML
Less Than $1000 mn
None None
None None
None None
YEZTUGO is indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating YEZTUGO
Yes
YEZTUGO Patent 1 Patent 2 Patent 3 Patent 4
*** *********

YEZTUGO - (300MG)

LENACAPAVIR None
300MG
Less Than $1000 mn
None None
None None
None None
None
No
YEZTUGO Patent 1 Patent 2 Patent 3
*** *********

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.